The peroxisome proliferator-activated receptor γ ligands, pioglitazone and 15-deoxy-Δ12,14-prostaglandin J2, have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 223-231

  Shim, Jaejun ^a   Kim, Byung Ho ^a   Kim, Young Il ^b   Kim, Kyung Yup ^a   Hwangbo, Young ^a   Jang, Jae Young ^a   Dong, Seok Ho ^a   Kim, Hyo Jong ^a   Chang, Young Woon ^a   Chang, Rin ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

15 deoxy 12,14 prostaglandin J2 (15d PGJ2); Antineoplastic agents; Hepatocellular carcinoma; Peroxisome proliferator activated receptor (PPAR ); Pioglitazone

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 9; CASPASE INHIBITOR; DNA FRAGMENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN BAX; PROTEIN BCL 2; ROSIGLITAZONE; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CELL ASSAY; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ETIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; HEPATITIS B VIRUS; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOLOGIC FACTORS; LIGANDS; LIVER NEOPLASMS; PPAR GAMMA; PROSTAGLANDIN D2; THIAZOLIDINEDIONES;

EID: 74549184686     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000493     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Jung SH, Kim BH, Joung YH, et al: Clinical features of hepatocellular carcinoma in the 1990s. Korean J Gastroenterol 42: 322-329, 2003.
3. Di Marco V, Lo Iacono O, Camma C, et al: The long-term course of chronic hepatitis B. Hepatology 30: 257-264, 1999.
4. Liaw YF, Tai DI, Chu CM and Chen TJ: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8: 493-496, 1988.
5. Fattovich G, Bortolotti F and Donato F: Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48: 335-352, 2008.
6. Benvegnu L, Gios M, Boccato S and Alberti A: Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53: 744-749, 2004.
7. Fattovich G, Giustina G, Schalm SW, et al: Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 21: 77-82, 1995.
8. Chang MH, Chen CJ, Lai MS, et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336: 1855-1859, 1997.
9. Liaw YF, Sung JJ, Chow WC, et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521-1531, 2004.
10. Schoonjans K, Staels B and Auwerx J: The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93-109, 1996.
11. Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5: 419-429, 2004.
12. Koga H, Sakisaka S, Harada M, et al: Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33: 1087-1097, 2001.
13. Rumi MA, Sato H, Ishihara S, et al: Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer 84: 1640-1647, 2001.
14. Toyoda M, Takagi H, Horiguchi N, et al: A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50: 563-567, 2002.
15. Scheen AJ: Thiazolidinediones and liver toxicity. Diabetes Metab 27: 305-313, 2001.
16. Isley WL: Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf 2: 581-586, 2003.
17. Belfort R, Harrison SA, Brown K, et al: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355: 2297-2307, 2006.
18. Bae MA, Rhee H and Song BJ: Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 139: 67-75, 2003.
19. Motomura W, Takahashi N, Nagamine M, et al: Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer 108: 41-46, 2004.
20. Okano H, Shiraki K, Inoue H, et al: Peroxisome proliferator-activated receptor gamma augments tumor necrosis factor family-induced apoptosis in hepatocellular carcinoma. Anticancer Drugs 13: 59-65, 2002.
21. Yoshizawa K, Cioca DP, Kawa S, Tanaka E and Kiyosawa K: Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 95: 2243-2251, 2002.
22. Lee JH, Ku JL, Park YJ, Lee KU, Kim WH and Park JG: Establishment and characterization of four human hepatocellular carcinoma cell lines containing hepatitis B virus DNA. World J Gastroenterol 5: 289-295, 1999.
23. Chae MJ, Shim J, Kim B-H, et al: Peroxisome proliferator-activated receptorγ ligands exert antineoplastic effects in hepatocellular carcinoma cells. Korean J Med 75: 288-299, 2008.
24. Freudlsperger C, Moll I, Schumacher U and Thies A: Antiproliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. Anticancer Drugs 17: 325-332, 2006.
25. Weng JR, Chen CY, Pinzone JJ, Ringel MD and Chen CS: Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 13: 401-413, 2006.
26. Chaffer CL, Thomas DM, Thompson EW and Williams ED: PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6: 53, 2006.
27. Cougot D, Neuveut C and Buendia MA: HBV induced carcinogenesis. J Clin Virol 34 (Suppl. 1): S75-S78, 2005.
28. Kim CM, Koike K, Saito I, Miyamura T and Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351: 317-320, 1991.
29. Kao JH, Chen PJ, Lai MY and Chen DS: Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124: 327-334, 2003.
30. Yu MW, Yeh SH, Chen PJ, et al: Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97: 265-272, 2005.
31. Sporn MB, Suh N and Mangelsdorf DJ: Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 7: 395-400, 2001.
32. Allred CD and Kilgore MW: Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 235: 21-29, 2005.
33. Guo L, Zhang L, Sun Y, et al: Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers 10: 349-360, 2006.
34. Akahori T, Sho M, Hamada K, et al: Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. J Hepatol 47: 784-792, 2007.
35. Borbath I, Leclercq I, Moulin P, Sempoux C and Horsmans Y: The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer 43: 1755-1763, 2007.
36. Ishihara S, Rumi MA, Okuyama T and Kinoshita Y: Effect of prostaglandins on the regulation of tumor growth. Curr Med Chem Anticancer Agents 4: 379-387, 2004.
37. Rossi A, Kapahi P, Natoli G, et al: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403: 103-108, 2000.
38. Nakata S, Yoshida T, Shiraishi T, et al: 15-Deoxy-Delta12,14- prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol Cancer Ther 5: 1827-1835, 2006.
39. Zander T, Kraus JA, Grommes C, et al: Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem 81: 1052-1060, 2002.
40. Yang FG, Zhang ZW, Xin DQ, et al: Peroxisome proliferator- activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 26: 753-761, 2005.